Pacira Pharmaceuticals, Inc.

Soroush M Ardekani

Kathleen D A Los

John J Grigsby, Jr

Jeffrey S Hall

David J Turnbull

Louie Daniel Garcia

Stephanie M Kurz

Paige N Davis

Ernest George Schutt

Eran Levy

Vladimir Kharitonov

Katherine Stone

Damon A Leon

Kathleen Dunne Albright Los

Alisha R Simonian

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

Manufacturing of bupivacaine multivesicular liposomes

Some embodiments of the present application are related to multivesicular liposome formulations comprising high concentration of bupivacaine for the purpose of preventing, treating or ameliorating pain, for example, post-surgical pain for an extended period of time. Processes of making and administering bupivacaine encapsulated multivesicular liposome formulations (BUP-MVLs) and their uses as medicaments are also provided.

Bupivacaine multivesicular liposome formulations and uses thereof

Some embodiments of the present application are related to multivesicular liposome (MVL) formulations encapsulating dexamethasone or an ester or an ester salt thereof, for example, dexamethasone sodium phosphate (DSP) that may provide about 3-28 days extended release of dexamethasone. Processes of making and administering dexamethasone encapsulated multivesicular liposome formulations and their uses for treating pain or inflammation are also provided.

Multivesicular liposome formulations of dexamethasone

Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.

Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and manufacturing processes for making bupivacaine MVLs.

Compositions of bupivacaine multivesicular liposomes

Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and commercial manufacturing processes for making bupivacaine MVLs.

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

Growing community of inventors

San Diego, CA, United States of America

Soroush M Ardekani